Loading data for ENOV — first visit, this takes a few seconds.

Preisalarm

Enovis Corporation (ENOV)

NYSE: ENOV · Echtzeitkurs · USD

26.17

-0.33 (-1.25%)

Zum Schluss: Aug 20, 2026, 6:50 PM

-1.25% (1D)

Keine Daten verfügbar

Geld	n/a
Marktkapitalisierung	1.51 Mrd
Umsatz (TTM)	2.3 Mrd
Nettogewinn (TTM)	-1.1 Mrd
Beta	1.45
EPS (ttm)	-19.27
KGV (TTM)	n/a
Forward-KGV	6.52
KBV (TTM)	1.02
KUV (TTM)	0.66
Earnings Date	n/a

Brief	n/a
Volumen	271,590
Ø Vol. (20D)	1,190,303
Eröffnung	26.20
Vortagesschluss	26.50
Tagesspanne	26.02 - 26.88
52-Wk Range	19.14 - 34.28
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über ENOV

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain mana...

[Mehr lesen]

Branche Medical Devices

Sektor Healthcare

IPO Datum May 8, 2008

Mitarbeiter 7,802

Börse NYSE

Tickersymbol ENOV

Website https://www.enovis.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Enovis 2.25 Mrd, ein Anstieg von 6.66% im Vergleich zum Vorjahr (2.11 Mrd). Der Gewinn lag bei -1.18 Mrd, ein Anstieg von 43.48 %.

Finanzberichte

Gewinnüberraschung

Enovis hat die Quartalszahlen am Aug 6, 2026 veröffentlicht:

Umsatz von $582.78 Mio verfehlt die Erwartungen um $0, mit 3.23% Wachstum im Jahresvergleich.

EPS von 0.9 übertrifft die Erwartungen um 0.05, mit 13.92% Wachstum im Jahresvergleich.

Nachrichten

vor 1 Woche · MarketBeat

Enovis Q2 Earnings Call Highlights

Enovis (NYSE:ENOV) reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Perfor...

vor 1 Woche · GuruFocus.com

Enovis Corp (ENOV) (Q2 2026) Earnings Call Highlights: Strong Innovation Drives 5% Organic ...

Enovis Corp (ENOV) delivers solid Q2 2026 results with US recon growing 6% and Avis gaining traction, while navigating inflationary pressures and softer European markets.

vor 2 Wochen · Zacks

Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates

Enovis (ENOV) delivered earnings and revenue surprises of +8.43% and +0.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

vor 2 Wochen · StockStory

Enovis (NYSE:ENOV) Posts Q2 CY2026 Sales In Line With Estimates

Medical technology company Enovis Corporation (NYSE:ENOV) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 3.2% year on year to $582.8 million. The company’s outlook for the full yea...

vor 2 Wochen · Zacks

Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates

Carlsmed, Inc. (CARL) delivered earnings and revenue surprises of +2.50% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Seite 1 von 2

Enovis Corporation (ENOV)